{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:08:25Z","timestamp":1779296905577,"version":"3.51.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The increasing use of immune checkpoint inhibitors (ICIs) for treating malignant tumors result in the concomitant rise of immune-related adverse events (irAEs). This case report may provide useful insight to understanding the etiology of ICI-induced hypophysitis, a severe irAE leading to potentially fatal secondary adrenal insufficiency.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>An 81-year-old Japanese man was hospitalized for diabetic ketoacidosis following 4 courses of ICI combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Insulin secretion was depleted, leading to diagnosis of fulminant type 1 diabetes. Adrenocorticotropic hormone (ACTH) and cortisol levels were very high (60.8 pmol\/L and 1575 nmol\/L, respectively) upon admission. ACTH and cortisol returned to normal ranges on the 2nd day. On the 8th day, an ACTH loading test showed intact cortisol response (peak value 519 nmol\/L). However, on the 14th day, there was a sharp decrease in ACTH and cortisol levels (10.5 pmol\/L and 47 nmol\/L, respectively) accompanied by fatigue and a drop in blood pressure to 97\/63\u2009mm Hg. As secondary adrenal insufficiency was suspected, hydrocortisone replacement was initiated. An ACTH loading test on the 17th day revealed low cortisol peak (peak value 232 nmol\/L), indicating sudden disruption of adrenal function. Magnetic resonance imaging showed no abnormal findings and there was no other pituitary hormone deficiency. These findings, along with the patient clinical course, suggest that secondary adrenal insufficiency was caused by acute ACTH producing cell destruction as an irAE associated with ICI therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient hyperglycemia and ketoacidosis were treated using extracellular fluid and insulin therapy. After development of adrenal insufficiency, hydrocortisone 20\u2009mg was started, and the patient symptoms improved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>He was continued on insulin therapy, hydrocortisone, and reinitiated nivolumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case provides a detailed course of the fulminant onset of ACTH deficiency during ICI administration, emphasizing the importance of close monitoring.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036664","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T19:03:23Z","timestamp":1703271803000},"page":"e36664","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1366-7555","authenticated-orcid":false,"given":"Hiroshi","family":"Iesaka","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-6688","authenticated-orcid":false,"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aika","family":"Miya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Yong","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashige","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.","volume":"4","author":"Lowe","year":"2016","journal-title":"J ImmunoTher Cancer"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.244.33","article-title":"Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, Nivolumab.","volume":"244","author":"Sakurai","year":"2018","journal-title":"Tohoku J Exp Med"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","article-title":"Fulminant type 1 diabetes associated with isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy.","volume":"66","author":"Okahata","year":"2019","journal-title":"Endocr J"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"e8426","DOI":"10.1097\/MD.0000000000008426","article-title":"Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review.","volume":"96","author":"Zeng","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1507\/endocrj.EJ19-0076","article-title":"Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.","volume":"66","author":"Sekizaki","year":"2019","journal-title":"Endocr J"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the Committee of the Japan Diabetes Society on the Research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus.","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2337\/diabetes.51.2.545","article-title":"Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes.","volume":"51","author":"Kawabata","year":"2002","journal-title":"Diabetes"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis.","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors.","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1002\/cam4.2661","article-title":"Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis.","volume":"8","author":"Lu","year":"2019","journal-title":"Cancer Med"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis.","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials.","volume":"10","author":"Da","year":"2020","journal-title":"Front Pharmacol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","article-title":"Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review.","volume":"57","author":"Ohara","year":"2018","journal-title":"Intern Med"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-Lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series.","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/07435800.2020.1817064","article-title":"Primary and ipilimumab-induced hypophysitis: a single-center case series.","volume":"45","author":"Atkins","year":"2020","journal-title":"Endocr Res"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy.","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","article-title":"Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses.","volume":"169","author":"Torino","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s11102-018-0880-8","article-title":"Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis.","volume":"21","author":"Sum","year":"2018","journal-title":"Pituitary"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1097\/MJT.0000000000000807","article-title":"Endocrinopathies related to immune checkpoint inhibitors.","volume":"26","author":"Khalid","year":"2019","journal-title":"Am J Ther"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade Anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome.","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/ajco.13573","article-title":"Autoimmune polyendocrine syndrome type 3, characterized by autoimmune thyroid disease, type 1 diabetes mellitus, and isolated ACTH deficiency, developed during adjuvant nivolumab treatment.","volume":"18","author":"Takata","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"993622","DOI":"10.3389\/fimmu.2022.993622","article-title":"Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: a case report and review of literature.","volume":"13","author":"Hino","year":"2022","journal-title":"Front Immunol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"993622","DOI":"10.1097\/MD.0000000000030398","article-title":"Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: a case report and review of 8 cases.","volume":"101","author":"Ishiguro","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"3000605221121940","DOI":"10.1177\/03000605221121940","article-title":"Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.","volume":"50","author":"Luo","year":"2022","journal-title":"J Int Med Res"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/j.jtho.2017.07.021","article-title":"Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response.","volume":"12","author":"Marchand","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13256-020-02502-w","article-title":"Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.","volume":"14","author":"Porntharukchareon","year":"2020","journal-title":"J Med Case Rep"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13256-020-02656-7","article-title":"Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.","volume":"15","author":"Kikuchi","year":"2021","journal-title":"J Med Case Rep"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/jdi.13604","article-title":"Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.","volume":"12","author":"Boswell","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/DMSO.S353403","article-title":"Autoimmune polyendocrinopathy induced by an antibody (KN046) that simultaneously inhibits PD-L1 and CTLA-4: a case report and literature review.","volume":"15","author":"Li","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:11:40Z","timestamp":1746317500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":34,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036664","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]}}}